ATE424842T1 - Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten - Google Patents
Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatientenInfo
- Publication number
- ATE424842T1 ATE424842T1 AT04797460T AT04797460T ATE424842T1 AT E424842 T1 ATE424842 T1 AT E424842T1 AT 04797460 T AT04797460 T AT 04797460T AT 04797460 T AT04797460 T AT 04797460T AT E424842 T1 ATE424842 T1 AT E424842T1
- Authority
- AT
- Austria
- Prior art keywords
- fragments
- bcl
- cancer patients
- family proteins
- proteins
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 title 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 102000007079 Peptide Fragments Human genes 0.000 abstract 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000051485 Bcl-2 family Human genes 0.000 abstract 1
- 108700038897 Bcl-2 family Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52311903P | 2003-11-19 | 2003-11-19 | |
DKPA200301716 | 2003-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE424842T1 true ATE424842T1 (de) | 2009-03-15 |
Family
ID=39149116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04797460T ATE424842T1 (de) | 2003-11-19 | 2004-11-18 | Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten |
Country Status (18)
Country | Link |
---|---|
US (1) | US7842294B2 (de) |
EP (2) | EP2087904B1 (de) |
JP (2) | JP4926714B2 (de) |
KR (2) | KR101216655B1 (de) |
CN (1) | CN1921878B (de) |
AT (1) | ATE424842T1 (de) |
AU (1) | AU2004290866B2 (de) |
CA (1) | CA2546794C (de) |
DE (1) | DE602004019965D1 (de) |
DK (2) | DK1691824T3 (de) |
ES (2) | ES2323588T3 (de) |
HK (1) | HK1101131A1 (de) |
MX (1) | MXPA06005738A (de) |
PL (2) | PL1691824T3 (de) |
PT (1) | PT1691824E (de) |
RU (1) | RU2367468C2 (de) |
WO (1) | WO2005049073A2 (de) |
ZA (1) | ZA200604866B (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
DK2359841T3 (en) * | 2003-01-30 | 2015-02-02 | Survac Aps | Survivin-derived peptides and the use thereof |
US20130052215A9 (en) | 2003-09-26 | 2013-02-28 | Eckhard Podack | Tumor vaccine |
WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
JP2008517070A (ja) * | 2004-10-19 | 2008-05-22 | マサチューセッツ インスティテュート オブ テクノロジー | 自己組織化式の可撓性かつ軽量のリチウム電池のためのウイルス骨格 |
JP2008528643A (ja) * | 2005-02-04 | 2008-07-31 | スルバック アーぺーエス | サバイビンペプチドワクチン |
AU2011203535B2 (en) * | 2005-02-04 | 2012-10-11 | Survac Aps | Survivin peptide vaccine |
WO2008039173A2 (en) * | 2005-09-09 | 2008-04-03 | Government Of The United States Of Amercica, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for inhibiting cell death or enhancing cell proliferation |
EP2361930A3 (de) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimere von peptide-mhc komplexen und deren verwendung in borrelia infektionskrankheiten |
EP3023436A1 (de) | 2007-07-03 | 2016-05-25 | Dako Denmark A/S | Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren |
WO2009039854A2 (en) * | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
EP2254592B1 (de) * | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc-multimere in borrelia-diagnostika und erkrankungen |
CA2723114C (en) | 2008-05-16 | 2018-02-27 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
CA2730369A1 (en) * | 2008-07-16 | 2010-01-21 | Burnham Institute For Medical Research | Compositions and methods for modulating nod-like receptor activity and uses thereof |
US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
DK2966084T3 (en) | 2008-08-28 | 2018-08-06 | Taiga Biotechnologies Inc | MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
WO2010037397A1 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
EP2337795A2 (de) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc-multimere in krebsimpfstoffen und der untersuchung der immunreaktion |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
EP2491116A4 (de) * | 2009-10-22 | 2013-12-11 | Univ Jefferson | Zellbasierte antikrebszusammensetzungen sowie verfahren zu ihrer herstellung und verwendung |
KR101872284B1 (ko) | 2010-03-11 | 2018-06-28 | 온코세라피 사이언스 가부시키가이샤 | Hjurp 펩티드 및 이를 포함한 백신 |
ES2722799T3 (es) | 2010-08-24 | 2019-08-16 | Univ Pittsburgh Commonwealth Sys Higher Education | Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13 |
EP4321218A3 (de) | 2012-05-16 | 2024-04-24 | Stemline Therapeutics, Inc. | Auf krebsstammzellen zielende krebsimpfstoffe |
US9789135B2 (en) * | 2012-07-20 | 2017-10-17 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US20160017011A1 (en) * | 2013-02-26 | 2016-01-21 | Rongfu Wang | Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy |
ES2859678T3 (es) * | 2013-03-01 | 2021-10-04 | Us Health | Métodos para producir poblaciones enriquecidas de células T reactivas a tumores a partir de un tumor |
US9704181B2 (en) * | 2014-05-06 | 2017-07-11 | International Business Machines Corporation | Real-time social group based bidding system |
KR20190092472A (ko) | 2016-12-02 | 2019-08-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | 나노입자 제제 |
TWI796314B (zh) * | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 |
US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
JP7337695B2 (ja) | 2017-01-27 | 2023-09-04 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチド組み合わせ |
MX2021002449A (es) | 2018-09-04 | 2021-08-05 | Treos Bio Ltd | Vacunas peptidicas. |
CN113355432A (zh) * | 2021-05-12 | 2021-09-07 | 甘肃农业大学 | Bmf作为细胞凋亡标志物的应用 |
WO2022245249A1 (ru) * | 2021-05-17 | 2022-11-24 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Пептидные соединения для индукции апоптоза в опухолевой клетке |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
EP0658113B1 (de) | 1992-08-31 | 2004-10-20 | Ludwig Institute For Cancer Research | Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen |
US5470955A (en) * | 1993-02-02 | 1995-11-28 | Dartmouth College | Antibodies which specifically bind mcl-1 polypeptide |
US5646008A (en) * | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
US5700638A (en) * | 1993-08-26 | 1997-12-23 | Washington University | Cell death regulator |
GB9320597D0 (en) | 1993-10-06 | 1993-11-24 | Proteus Molecular Design | Improvements in and realting to vaccines |
US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
US5789201A (en) * | 1996-02-23 | 1998-08-04 | Cocensys, Inc. | Genes coding for bcl-y a bcl-2 homologue |
WO1998022589A2 (en) | 1996-11-20 | 1998-05-28 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
WO1998058541A1 (en) | 1997-06-24 | 1998-12-30 | Dana-Farber Cancer Institute, Inc. | Modulation of apoptosis |
WO2001036594A1 (en) | 1999-11-16 | 2001-05-25 | Dartmouth College | Mcl-1 GENE REGULATORY ELEMENTS AND A PRO-APOPTOTIC Mcl-1 VARIANT |
EP1238080A2 (de) | 1999-12-14 | 2002-09-11 | The Burnham Institute | Bcl-g polypeptide, kodierende nukleine säuren und verfahren zur anwendungen |
WO2002005835A2 (en) * | 2000-07-17 | 2002-01-24 | Washington University | Modulation of apoptosis |
AU2002257647A1 (en) | 2001-03-09 | 2002-09-24 | Callistogen Ag | Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
EP1618130B1 (de) | 2003-04-11 | 2013-03-27 | Survac ApS | Therapeutischer krebsimpfstoff |
-
2004
- 2004-11-18 JP JP2006540170A patent/JP4926714B2/ja active Active
- 2004-11-18 DE DE602004019965T patent/DE602004019965D1/de active Active
- 2004-11-18 CN CN2004800407050A patent/CN1921878B/zh active Active
- 2004-11-18 CA CA2546794A patent/CA2546794C/en active Active
- 2004-11-18 MX MXPA06005738A patent/MXPA06005738A/es active IP Right Grant
- 2004-11-18 ZA ZA200604866A patent/ZA200604866B/en unknown
- 2004-11-18 PT PT04797460T patent/PT1691824E/pt unknown
- 2004-11-18 EP EP09154734.9A patent/EP2087904B1/de active Active
- 2004-11-18 WO PCT/DK2004/000799 patent/WO2005049073A2/en active Application Filing
- 2004-11-18 RU RU2006121466/15A patent/RU2367468C2/ru active
- 2004-11-18 EP EP04797460A patent/EP1691824B1/de active Active
- 2004-11-18 KR KR1020067012186A patent/KR101216655B1/ko active IP Right Grant
- 2004-11-18 AU AU2004290866A patent/AU2004290866B2/en active Active
- 2004-11-18 DK DK04797460T patent/DK1691824T3/da active
- 2004-11-18 DK DK09154734.9T patent/DK2087904T3/da active
- 2004-11-18 KR KR1020127016885A patent/KR101284237B1/ko active IP Right Grant
- 2004-11-18 US US10/580,016 patent/US7842294B2/en active Active
- 2004-11-18 AT AT04797460T patent/ATE424842T1/de active
- 2004-11-18 PL PL04797460T patent/PL1691824T3/pl unknown
- 2004-11-18 ES ES04797460T patent/ES2323588T3/es active Active
- 2004-11-18 PL PL09154734T patent/PL2087904T3/pl unknown
- 2004-11-18 ES ES09154734.9T patent/ES2436429T3/es active Active
-
2007
- 2007-08-23 HK HK07109167.1A patent/HK1101131A1/xx unknown
-
2011
- 2011-09-12 JP JP2011198605A patent/JP5502823B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE424842T1 (de) | Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten | |
CY1119127T1 (el) | Επιτοποι σκληροστινης | |
ATE486087T1 (de) | Fgf-5-bindende und geträgerte peptide | |
CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
CA2523467C (en) | Treatment of t-cell mediated diseases | |
MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
WO2007034489A3 (en) | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom | |
DE60032486D1 (de) | Prion protein peptide und deren verwendung | |
DK1545613T3 (da) | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom | |
EP2182006A3 (de) | Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen | |
NO20045521L (no) | Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer | |
ATE549353T1 (de) | Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen | |
DE60230456D1 (de) | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren | |
EA200801411A1 (ru) | Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях | |
ATE543833T1 (de) | Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen | |
DK2229440T3 (da) | Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf | |
WO2006137938A3 (en) | Antibody fragments for protection from pathogen infection and methods of use thereof | |
NO20060781L (no) | Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser | |
WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
ATE467421T1 (de) | Cytokine und cytokinrezeptoren mit reduzierter immunogenität | |
ATE505538T1 (de) | Dna-vektoren | |
CY1108761T1 (el) | Απενεργοποιημενες κυτοκινες για ανοσοποιηση | |
DE60229924D1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten | |
ITFI20030238A1 (it) | Peptidi ciclici antagonisti dell'urotensina-ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1691824 Country of ref document: EP |
|
EEIH | Change in the person of patent owner |